[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 2, 1994

The Breast Cancer Prevention Trial: A Correction

Author Affiliations

Southeast Cancer Control Consortium Winston-Salem, NC

JAMA. 1994;272(17):1328. doi:10.1001/jama.1994.03520170038030

To the Editor.  —Mr Marwick1 stated that the Breast Cancer Prevention Trial was "investigating the value of tamoxifen in preventing breast cancer in the contralateral breast of women who have had the disease." This obviously is incorrect.Two different National Surgical Adjuvant Breast and Bowel Cancer Project (NSABP) trials were mixed up. The Breast Cancer Prevention Trial is investigating the value of tamoxifen citrate in preventing breast cancer in women who are at high risk for the development of breast cancer who have never had invasive disease. To my knowledge, NSABP has never had a study that was designed to try to prevent contralateral breast cancer. NSABP B-14 did demonstrate that using tamoxifen results in a 40% to 50% decrease in the incidence of contralateral breast cancer, but the objective of that study was to determine the worth of using tamoxifen in stage I breast cancer patients.

First Page Preview View Large
First page PDF preview
First page PDF preview